Currently, chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and is common in resource-poor countries.

Revefenacin was found to have the potential to serve as long-acting bronchodilator for once-daily treatment of respiratory disorders such as chronic obstructive pulmonary disease (COPD), according to a review of the drug’s effects in Cureus.

The goal of pharmacological therapy in COPD is to reduce the frequency and severity of exacerbations, relieve debilitating symptoms, and improve the overall health of individuals with the disease.

Nebulized therapy options for treatment of COPD are currently limited and use of hand-held devices can result in poor adherence, inaccurate dosing, and poor clinical outcomes.

However, revefenacin, sold as Yupelri by Theravance Biopharma, offers an opportunity for patients that prefer or require nebulized therapy to be treated with a potent, once-daily long-acting muscarinic antagonist (LAMA). Revefenacin is the first and only once-daily nebulized bronchodilator approved by the FDA to treat COPD.

Glad to share that we have achieved the research on the intermediates of Revefenacin:

Product Name:2-Biphenylyl isocyanate

CAS No.17337-13-2

Others intermediates are also under development:
CAS No. 171722-92-2

CAS No. 864686-28-2

CAS No. 743460-48-2

If any demand,welcome to contact for more information!